Law Offices of Thomas J. Lamb

  • About Firm
  • Practice Areas
  • Free Case Evaluation
  • Quick Contact Form
  • Frequently Asked Questions
  • Attorney Tom Lamb

Ozempic Vision Loss Lawsuits Against Novo Nordisk

May 6, 2025 By Law Offices of Thomas J. Lamb, P.A.

Patients who are filing Ozempic vision loss lawsuits against Novo Nordisk had developed nonarteritic anterior ischemic optic neuropathy (NAION) while using Ozempic. These cases are product liability failure to warn lawsuits filed against the responsible drug company, Novo Nordisk, because the Ozempic drug label does not warn about NAION as a … [Read more...]

Filed Under: Unsafe Drugs Tagged With: Nonarteritic Anterior Ischemic Optic Neuropathy (NAION), Ozempic, Rybelsus, vision loss, Wegovy

Diagnostic Differentiation Between Two Rare Entities—Metastatic Peritoneal Mesothelioma With Duodenal Involvement and Duodenal Synovial Sarcoma: A Case Report

April 23, 2025 By Law Offices of Thomas J. Lamb, P.A.

Abstract:  This case report highlights the diagnostic challenges in distinguishing between metastatic peritoneal mesothelioma with duodenal involvement and synovial sarcoma of the duodenum, two rare and complex entities. A 59-year-old woman presented with nonspecific abdominal symptoms, and imaging revealed a heterogeneous lesion between the right … [Read more...]

Filed Under: Mesothelioma Tagged With: mesothelioma, peritoneal mesothelioma

Vision Loss Linked to Rybelsus and Ozempic Use by Diabetes Patients

April 15, 2025 By Law Offices of Thomas J. Lamb, P.A.

The relatively new drug safety issue of vision loss linked to Rybelsus and Ozempic was the subject of a recent medical study that had this stated Objective, or purpose: “To investigate the association between semaglutide use and the risk of NAION among patients with diabetes.” On March 27, 2025, the JAMA Ophthalmology medical journal published … [Read more...]

Filed Under: Unsafe Drugs Tagged With: Nonarteritic Anterior Ischemic Optic Neuropathy (NAION), Ozempic, Rybelsus, vision loss

A Review of Job Assignments and Asbestos Workplace Exposure Measurements for TAWP Mesothelioma Deaths Through 2011

March 28, 2025 By Law Offices of Thomas J. Lamb, P.A.

ABSTRACT Introduction: Asbestos workers have a higher risk of developing mesothelioma; however, few studies have looked at specific jobs and job locations within asbestos factories. The purpose of this study was to investigate asbestos exposure in different job locations of the Tyler, Texas asbestos plant to determine if there was a relationship … [Read more...]

Filed Under: Asbestos, Mesothelioma Tagged With: asbestos exposure, mesothelioma

Multimodality Therapy Including Pleurectomy/Decortication in Pleural Mesothelioma: Long-Term Outcomes in 152 Consecutive Patients A Retrospective Cohort Study

March 6, 2025 By Law Offices of Thomas J. Lamb, P.A.

Objective:  Evaluate the long-term outcomes of pleurectomy decortication, systemic chemotherapy and prophylactic radiotherapy in pleural mesothelioma (PM). Summary background data:  There is no known cure for PM and cytoreductive surgery remains controversial. Methods:  Retrospective analysis of a cohort of patients treated consecutively … [Read more...]

Filed Under: Mesothelioma Tagged With: chemotherapy, decortication, mesothelioma treatments, pleural mesothelioma, pleurectomy, radiotherapy

Semaglutide: Eyesight Loss From Drug Side Effect NAION

February 26, 2025 By Law Offices of Thomas J. Lamb, P.A.

Semaglutide eyesight loss from the drug side effect NAION is being investigated as possible drug injury lawsuits to be filed on behalf of patients against Novo Nordisk, the responsible drug company for Ozempic, Wegovy, and Rybelsus.  The active ingredient for each of those three Novo Nordisk drugs is semaglutide. There are a couple of recent … [Read more...]

Filed Under: Unsafe Drugs Tagged With: Nonarteritic Anterior Ischemic Optic Neuropathy (NAION), Ozempic, Rybelsus, Wegovy

Recent Advances in Mesothelioma Treatment: Immunotherapy, Advanced Cell Therapy, and Other Innovative Therapeutic Modalities

February 20, 2025 By Law Offices of Thomas J. Lamb, P.A.

Mesothelioma is a malignant condition arising from the pleura and peritoneum that is closely related to asbestos exposure. Due to the prolonged time needed for one to fully develop mesothelioma, difficulty in diagnosing this condition early, its quick progression once manifested, and the limited treatment options, the prognosis for this condition … [Read more...]

Filed Under: Mesothelioma Tagged With: mesothelioma, mesothelioma treatments

Depo-Provera Meningioma Increased Risk Warning in Europe

February 11, 2025 By Law Offices of Thomas J. Lamb, P.A.

The European Medicines Agency (EMA) recommended a Depo-Provera meningioma increased risk warning in September 2024. One wonders why the FDA has not followed this EMA regulatory action. Therefore, the Depo-Provera drug label in the US still does not include a warning about the meningioma increased risk associated with Depo-Provera. The following … [Read more...]

Filed Under: Unsafe Drugs Tagged With: Depo-Provera, intracranial meningioma

Treatment of Pleural Mesothelioma: ASCO Guideline Update

February 3, 2025 By Law Offices of Thomas J. Lamb, P.A.

Since the initial [American Society of Clinical Oncologists (ASCO)] clinical practice guideline on the treatment of malignant pleural mesothelioma (PM) was published in 2018 considerable progress has been made which has changed not only the management but even the name of this disease. This guideline update focuses on four key areas: the role of … [Read more...]

Filed Under: Mesothelioma Tagged With: malignant pleural mesothelioma (MPM), mesothelioma, mesothelioma treatments

Why Are There Depo-Provera Brain Tumor Warnings In Europe But Not US?

February 3, 2025 By Law Offices of Thomas J. Lamb, P.A.

Depo-Provera brain tumor lawsuits for women who have been diagnosed with intracranial meningioma, a specific type of brain tumor, are being filed against the responsible pharmaceutical companies. A primary focus of these legal cases will be why the Depo-Provera drug label in the US does not include any warnings about the increased risk of this … [Read more...]

Filed Under: Unsafe Drugs Tagged With: brain tumors, Depo-Provera, intracranial meningioma

  • 1
  • 2
  • 3
  • …
  • 22
  • Next Page »

Find What You Want Here

Get Free Case Evaluation

We encourage you to submit an online Case Evaluation Form – it is confidential and there is no obligation.

Or call our toll-free number, 800-426-9535, to speak directly to attorney Tom Lamb about your possible case.

Feel Free To Contact Us

Quick Contact Form
 
Send an Email to Tom Lamb

(800) 426-9535

Main Navigation Menu

  • About Firm
  • Asbestos-Mesothelioma Cases
  • Benzene Disease Claims
  • Drug Injury Lawsuits
  • Breast Implant Cancer Cases
  • Case Evaluation Menu
  • Quick Contact Form
  • Frequently Asked Questions
  • Medical Records Charges
  • Collection of Articles
  • Sitemap

Lamb Law Office Newsletter

Lamb Law Office Newsletter provides periodic updates about some of the cases that we are working on for clients, as well as an information resource you might find helpful.

Subscribe using Form below.

Subscription Form

* indicates required

Our Other Websites

DrugInjuryLaw.com

DrugInjuryWatch.com

Asbestos-Mesothelioma.com

Contact Information

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, North Carolina 28403
910-256-2971 | 800-426-9535
TJL@LambLawOffice.com

  • Home
  • Disclaimer and Copyright Notices
  • Sitemap

Copyright © 2025 · Law Offices of Thomas J. Lamb, P.A.